Literature DB >> 17125034

[Trials of casual treatment of silicosis].

Iwona Idec-Sadkowska1, Ryszard Andrzejak, Jolanta Antonowicz-Juchniewicz, Beata Kaczmarek-Wdowiak.   

Abstract

Silica-induced lung injury and the development of silicosis is one of the major occupational diseases. Accumulation and deposition of respirable dust containing silica mineral particles in the lung produces chronic lung disease characterized by granulomatous and fibrotic lesions. Knowledge of precise mechanisms, which induce this process is still limited, hence problems faced in the treatment of silicosis, especially the casual one. This article describes various trials of casual silicosis treatment with tetrandrine (Tet), isolated from the root of Stephania tetrandra, tumor necrosis factor (TNF) antagonists, polyvinyl-pyridine-N-oxide (PVNO), aluminum compounds, corticosteroids or bronchoalveolar lavage (BAL). The existing methods are not sufficient, which warrants further investigations. At present, prevention of the disease and treatment of its complications are most important.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17125034

Source DB:  PubMed          Journal:  Med Pr        ISSN: 0465-5893            Impact factor:   0.760


  3 in total

1.  Tetrandrine alleviates symptoms of rheumatoid arthritis in rats by regulating the expression of cyclooxygenase-2 and inflammatory factors.

Authors:  Xiang Li; Zhongxiu Wu; Bin He; Wei Zhong
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

Review 2.  Cell-Based Therapy for Silicosis.

Authors:  Miquéias Lopes-Pacheco; Elga Bandeira; Marcelo M Morales
Journal:  Stem Cells Int       Date:  2016-03-15       Impact factor: 5.443

Review 3.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.